Clinical trial · Interventional
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914)
NCT00978146CI-TRIAL-00027103withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was administratively withdrawn by the IRB; no subjects were enrolled
Summary
Brief summary (as posted)
The purpose of this study is to examine the response rate of desmoid tumors to hydroxyurea. The investigators hypothesize that hydroxyurea will be a safe, non-toxic alternative to aggressive surgery or chemotherapy for this difficult to treat tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Desmoid Tumors | Desmoid Fibromatosis | ALIAS | 0.90 |
| Fibromatosis | Fibromatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hydroxyurea | Drug | Hydroxyurea | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Desmoid tumor
- description
- Patients with desmoid tumors
- interventionNames
- Drug: Hydroxyurea
Primary outcomes (1)
- measure
- The primary outcome of this study is change in tumor size.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \</= 21 years of age will be eligible * Histologically-confirmed diagnosis of desmoid tumor * Measurable disease * Stable hematologic, renal and hepatic parameters * Negative pregnancy test for women of childbearing potential Exclusion Criteria: * Presence of a second neoplastic process * Pregnant or breastfeeding women, fetuses, and prisoners will not be included in this study * Patients receiving additional treatment for tumor other than pain control * Patients having taken an investigational drug within the past 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.